fashion -WSS

fashion

author：comprehensive 2025-10-01 00:00:17 - browse：588

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： A common UTI test for kids haunts adults as a traumatic 'nightmare'

explore

WSS

Regeneron agrees to White House price limits on anti

Pig kidney works a record two months in donated body

Readout Newsletter: Beam, Prozac, "TechBio" and more

Children’s Hospital revives plan for pedestrian bridge

Pig kidney works a record two months in donated body

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

entertainment

fashion

focus

Supreme Court strikes down use of affirmative action

Will the IRA bring competition to the biologics market?

How one medical school became remarkably diverse

How housing is health care on Long Island

The cancer drug shortage isn’t new — and neither are the solutions

Childhood vaccination ad campaign launches in the U.K.

The high cost of giving birth even with insurance

Hospitals consider fixing cancer drug shortages on their own

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CDC advisory group OKs chikungunya vaccine

entertainment

5 ways to address the shortage of health care workers

Private equity could exacerbate cardiology's overuse problem, experts fear

Walmart eyes Medicare Advantage provider ChenMed

Will the IRA bring competition to the biologics market?

New Covid vaccine is recommended for everyone 6 months or older

New Covid vaccine is recommended for everyone 6 months or older

entertainment

hotspot

explore

Wikipedia